Immunoglobulin light-chain amyloidosis (AL amyloidosis) is a rare disease in which a small plasma cell clone produces toxic misfolded proteins that deposit in organs and impair their function. Currently, the only available treatment approach is the elimination of clonal plasma cells. However, a rapid strike that halts and possibly reverses organ damage is crucial. The development of agents that facilitate the clearance of pathological fibrillar deposits, therefore reducing the frailty of patients, is the needed supplement to plasma cell-directed therapy. Monoclonal antibodies provide therapy against malignant plasma cells (daratumumab, isatuximab, elotuzumab) but they are also able to target and eliminate the amyloid from organs (NEOD001, CAEL-101, dezamizumab). From the plasma cell-directed group, daratumumab in monotherapy has proved to be extremely efficient in relapsed AL amyloidosis, exceeding its results in multiple myeloma. Compared to other agents, monoclonal antibodies possess the advantage of high selectivity and low toxicity and could potentially become future game-changers in this field. Co-targetting of the plasma cell clone and amyloid deposits shall together be translated in the revolutionary improved outcome of potentially curable AL amyloidosis.

Department of Haematooncology University Hospital Ostrava and Faculty of Medicine Ostrava Czech Republic

Faculty of Medicine University of Ostrava Ostrava Czech Republic

Faculty of Science University of Ostrava Ostrava Czech Republic

See more in PubMed

Abeykoon, J.P., Zanwar, S., Dispenzieri, A., Gertz, M.A., Leung, N., Kourelis, T., Gonsalves, W., Muchtar, E., Dingli, D., Lacy, M.Q., Hayman, S.R., Buadi, F., Warsame, R., Kyle, R.A., Rajkumar, V., Kumar, S. & Kapoor, P. (2018) Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis. Leukemia33, 531-536.

Bhutani, D., Leng, S., Eisenberger, A., Maurer, M.S., Shames, S., Goldsmith, J. & Lentzsch, S. (2018) Improvement in Global Longitudinal Strain (GLS) correlates with NT-Probnp response in patients with cardiac amyloidosis treated on a Phase 1b study of anti-amyloid Mab Cael-101. Blood, 132, 958-958.

Bochtler, T., Hegenbart, U., Kunz, C., Benner, A., Seckinger, A., Dietrich, S., Granzow, M., Neben, K., Goldschmidt, H., Ho, A.D., Hose, D., Jauch, A. & Schönland, S.O. (2014) Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid, 21, 9-17.

Bochtler, T., Hegenbart, U., Kunz, C., Granzow, M., Benner, A., Seckinger, A., Kimmich, C., Goldschmidt, H., Ho, A.D., Hose, D., Jauch, A. & Schönland, S.O. (2015) Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. Journal of Clinical Oncology, 33, 1371-1378.

Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., Hutchinson, W.L., Mangione, P.P., Gallimore, J.R., Millar, D.J., Minogue, S., Dhillon, A.P., Taylor, G.W., Bradwell, A.R., Petrie, A., Gillmore, J.D., Bellotti, V., Botto, M., Hawkins, P.N. & Pepys, M.B. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature, 468, 93-97.

Braet, H., Zwaenepoel, O. & Gettemans, J. (2018) Serum amyloid P component nanobodies a new tool in amyloid research. In Kumamoto, Japan.

Brenner, D.A., Jain, M., Pimentel, D.R., Wang, B., Connors, L.H., Skinner, M., Apstein, C.S. & Liao, R. (2004) Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circulation Research, 94, 1008-1010.

Comenzo, R., Kastritis, E., Maurer, M., Zonder, J., Minnema, M.C., Wechalekar, A., Palladini, G., Qin, X., Vasey, S., Aschan, J., Vermeulen, J. & Merlini, G. (2019) Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (CYBORD) in patients with newly diagnosed amyloid light chain (AL) amyloidosis: updated safety run-in results of andromeda. Amsterdam, Available at: https://library.ehaweb.org/eha/2019/24th/267458/raymond.l.comenzo.subcutaneous.daratumumab.2B.cyclophosphamide.bortezomib.and.html?f=listing%3D3%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1550 [Accessed July 8, 2019].

Cuesta-Mateos, C., Alcaraz-Serna, A., Somovilla-Crespo, B. & Muñoz-Calleja, C. (2018) Monoclonal antibody therapies for hematological malignancies: not just lineage-specific targets. Frontiers in Immunology, 8, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5776327/ [Accessed February 22, 2019].

D’Souza, A., Dispenzieri, A., Wirk, B., Zhang, M.-J., Huang, J., Gertz, M.A., Kyle, R.A., Kumar, S., Comenzo, R.L., Peter Gale, R., Lazarus, H.M., Savani, B.N., Cornell, R.F., Weiss, B.M., Vogl, D.T., Freytes, C.O., Scott, E.C., Landau, H.J., Moreb, J.S., Costa, L.J., Ramanathan, M., Callander, N.S., Kamble, R.T., Olsson, R.F., Ganguly, S., Nishihori, T., Kindwall-Keller, T.L., Wood, W.A., Mark, T.M. & Hari, P. (2015) Improved Outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a center for international blood and marrow transplant research study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 3741-3749.

Deckert, J., Wetzel, M.-C., Bartle, L.M., Skaletskaya, A., Goldmacher, V.S., Vallée, F., Zhou-Liu, Q., Ferrari, P., Pouzieux, S., Lahoute, C., Dumontet, C., Plesa, A., Chiron, M., Lejeune, P., Chittenden, T., Park, P.U. & Blanc, V. (2014) SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 20, 4574-4583.

Dimopoulos, M.A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N.J., Usmani, S.Z., Rabin, N., Orlowski, R.Z., Komarnicki, M., Suzuki, K., Plesner, T., Yoon, S.-S., Ben Yehuda, D., Richardson, P.G., Goldschmidt, H., Reece, D., Lisby, S., Khokhar, N.Z., O’Rourke, L., Chiu, C., Qin, X., Guckert, M., Ahmadi, T., Moreau, P.& POLLUX Investigators (2016) Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. The New England Journal of Medicine, 375, 1319-1331.

Dispenzieri, A., Buadi, F., Kumar, S.K., Reeder, C.B., Sher, T., Lacy, M.Q., Kyle, R.A., Mikhael, J.R., Roy, V., Leung, N., Grogan, M., Kapoor, P., Lust, J.A., Dingli, D., Go, R.S., Hwa, Y.L., Hayman, S.R., Fonseca, R., Ailawadhi, S., Bergsagel, P.L., Chanan-Khan, A., Rajkumar, V.S., Russell, S.J., Stewart, K., Zeldenrust, S.R. & Gertz, M.A. (2015) Treatment of immunoglobulin light chain amyloidosis: mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clinic Proceedings, 90, 1054-1081.

van de Donk, N.W.C.J., Janmaat, M.L., Mutis, T., Lammerts van Bueren, J.J., Ahmadi, T., Sasser, A.K., Lokhorst, H.M. & Parren, P.W.H.I. (2016) Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunological Reviews, 270, 95-112.

Duhamel, S., Mohty, D., Magne, J., Lavergne, D., Bordessoule, D., Aboyans, V. & Jaccard, A. (2017) Incidence and prevalence of light chain amyloidosis: a population-based study. Blood, 130, 5577-5577.

Edwards, C.V., Gould, J., Langer, A.L., Mapara, M., Radhakrishnan, J., Maurer, M.S., Raza, S., Mears, J.G., Wall, J.S., Solomon, A. & Lentzsch, S. (2016) Analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Blood, 128, 643-643.

Edwards, C.V., Bhutani, D., Mapara, M., Radhakrishnan, J., Shames, S., Maurer, M.S., Leng, S., Wall, J.S., Solomon, A., Eisenberger, A. & Lentzsch, S. (2019) One year follow up analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis. Amyloid: The International Journal of Experimental and Clinical Investigation: The Official Journal of the International Society of Amyloidosis, 26, 115-116.

Feng, X., Zhang, L., Acharya, C., An, G., Wen, K., Qiu, L., Munshi, N.C., Tai, Y.-T. & Anderson, K.C. (2017) Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clinical Cancer Research, 23, 4290-4300.

Fu, J., Solomon, A., Carberry, P., Castrillon, J., Kim, J., Lentzsch, S. & Mintz, A. (2018) Personalizing amyloidosis therapy with real time PET imaging of fibril-reactive monoclonal antibody cael-101. Blood, 132, 1003-1003.

Gavriatopoulou, M., Musto, P., Caers, J., Merlini, G., Kastritis, E., van de Donk, N., Gay, F., Hegenbart, U., Hajek, R., Zweegman, S., Bruno, B., Straka, C., Dimopoulos, M.A., Einsele, H., Boccadoro, M., Sonneveld, P., Engelhardt, M. & Terpos, E. (2018) European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia, 32, 1883-1898.

Gertz, M.A., Comenzo, R.L., Landau, H., Sanchorawala, V., Weiss, B.M., Zonder, J.A., Walling, J., Kinney, G.G., Koller, M., Schenk, D.B., Guthrie, S.D., Liu, E. & Liedtke, M. (2016) NEOD001 demonstrates organ biomarker responses in patients with light chain amyloidosis and persistent organ dysfunction: results from the expansion cohort of a phase 1/2 study. Blood, 128, 644-644.

Ghilardi, G., Stussi, G., Mazzucchelli, L., Röcken, C., Rossi, D. & Gerber, B. (2019) Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). Amyloid, 26, 173-174.

Gillmore, J.D., Tennent, G.A., Hutchinson, W.L., Gallimore, J.R., Lachmann, H.J., Goodman, H.J.B., Offer, M., Millar, D.J., Petrie, A., Hawkins, P.N. & Pepys, M.B. (2010) Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology, 148, 760-767.

Godara, A., Siddiqui, N., Lee, L., Toskic, D., Fogaren, T., Varga, C. & Comenzo, R. (2019) Combined use of two monoclonal antibodies in patients with systemic AL amyloidosis and cardiac involvement. Chicago, Available at: http://abstracts.asco.org/239/AbstView_239_263947.html [Accessed July 8, 2019].

Hrncic, R., Wall, J., Wolfenbarger, D.A., Murphy, C.L., Schell, M., Weiss, D.T. & Solomon, A. (2000) Antibody-mediated resolution of light chain-associated amyloid deposits. The American Journal of Pathology, 157, 1239-1246.

Iqbal, S.M., Stecklein, K., Sarow, J., Krabak, M., Hillengass, J. & McCarthy, P. (2019) Elotuzumab in combination with lenalidomide and dexamethasone for treatment-resistant immunoglobulin light chain amyloidosis with multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 19, e33-e36.

Jaccard, A., Arnulf, B., Stoppa, A.-M., Karlin, L., Perrot, A., Macro, M., Huart, A., Frenzel, L., Morel, P., Dorvaux, V., Merlini, G., Palladini, G., Lavergne, D., Bridoux, F. & Rousselle, M. (2018) A prospective Phase II study of daratumumab in previously-treated. In room A1. Available at: https://learningcenter.ehaweb.org/eha/2018/stockholm/214545/arnaud.jaccard.a.prospective.phase.ii.study.of.daratumumab.in.html?f=topic=1574*media=3 [Accessed February 14, 2019].

Jelinek, T. & Hajek, R. (2016) Monoclonal antibodies - a new era in the treatment of multiple myeloma. Blood Reviews, 30, 101-110.

Jelinek, T., Kufova, Z. & Hajek, R. (2016) Immunomodulatory drugs in AL amyloidosis. Critical Reviews in Oncology/Hematology, 99, 249-260.

Jelinek, T., Bezdekova, R., Zatopkova, M., Burgos, L., Simicek, M., Sevcikova, T., Paiva, B. & Hajek, R. (2017a) Current applications of multiparameter flow cytometry in plasma cell disorders. Blood Cancer Journal, 7, e617.

Jelinek, T., Kryukova, E., Kufova, Z., Kryukov, F. & Hajek, R. (2017b) Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity. Hematological Oncology, 35, 408-419.

Jelínek, T., Mihalyova, J. & Hajek, R. (2018) CD38 cílená léčba u mnohočetného myelomu. Vnitřní lékařství, 64, 939-948.

Kastritis, E., Leleu, X., Arnulf, B., Zamagni, E., Cibeira, M.T., Kwok, F., Mollee, P., Hajek, R., Moreau, P., Jaccard, A., Schönland, S., Filshie, R., Nicolas-Virelizier, E., Augustson, B., Mateos, M.-V., Wechalekar, A., Hachulla, E., Milani, P., Dimopoulos, M.A., Fermand, J.-P. et al (2016) A Randomized Phase III trial of melphalan and dexamethasone (MDex) versus bortezomib, melphalan and dexamethasone (BMDex) for untreated patients with AL amyloidosis. Blood, 128, 646-646.

Kastritis, E., Gavriatopoulou, M., Kostopoulos, I., Dialoupi, I., Roussou, M., Kanellias, N., Fotiou, D., Eleutherakis-Papaiakovou, E., Ntanasis-Stathopoulos, I., Miqkou, M., Ziogas, D.C., Papanota, A.-M., Papanikolaou, A., Gakiopoulou, C., Psimenou, E., Tseleqkidi, M., Tsitsilonis, O., Trouqakos, I., Terpos, E. & Dimopoulos, M. (2019) Consolidation with a short course of daratumumab can significantly improve complete response rates in patients with AL amyloidosis or LCDD. Amsterdam, Available at: https://library.ehaweb.org/eha/2019/24th/267009/efstathios.kastritis.consolidation.with.a.short.course.of.daratumumab.can.html?f=menu%3D6%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Ace_id%3D1550%2Aot_id%3D20963 [Accessed July 8, 2019].

Kaufman, G.P., Schrier, S.L., Lafayette, R.A., Arai, S., Witteles, R.M. & Liedtke, M. (2017) Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood, 130, 900-902.

Khouri, J., Kin, A., Thapa, B., Reu, F.J., Bumma, N., Samaras, C.J., Liu, H.D., Karam, M.A., Reed, J., Mathur, S., Faiman, B.M., Devries, G., Zonder, J. & Valent, J. (2018) Daratumumab proves safe and highly effective in AL amyloidosis. British Journal of Haematology, 185, 342-344.

Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., Laumann, K., Zeldenrust, S.R., Leung, N., Dingli, D., Greipp, P.R., Lust, J.A., Russell, S.J., Kyle, R.A., Rajkumar, S.V. & Gertz, M.A. (2012) Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 30, 989-995.

Liedtke, M., Comenzo, R.L., Landau, H., Sanchorawala, V., Weiss, B.M., Zonder, J.A., Walling, J., Kinney, G.G., Koller, M., Schenk, D.B., Guthrie, S.D., Liu, E. & Gertz, M.A. (2016a) Organ biomarker responses in patients with light chain amyloidosis treated with NEOD001 are independent of previous hematologic response. Blood, 128, 647-647.

Liedtke, M., Merlini, G., Landau, H., Comenzo, R.L., Sanchorawala, V., Weiss, B.M., Zonder, J.A., Walling, J., Kinney, G.G., Koller, M. & Gertz, M.A. (2016b) The VITAL amyloidosis study: a randomized, double-blind, placebo-controlled, global, Phase 3 study of NEOD001 in patients with AL amyloidosis and cardiac dysfunction. Blood, 128, 5690-5690.

Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., Belch, A., Reece, D., Beksac, M., Spencer, A., Oakervee, H., Orlowski, R.Z., Taniwaki, M., Röllig, C., Einsele, H., Wu, K.L., Singhal, Anil, San-Miguel, Jesus, Matsumoto, Morio, Katz, Jessica, Bleickardt, Eric, Poulart, Valerie, Anderson, Kenneth C., Richardson, P. & ELOQUENT-2 Investigators (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. New England Journal of Medicine, 373, 621-631.

Martin, T., Baz, R., Benson, D.M., Lendvai, N., Wolf, J., Munster, P., Lesokhin, A.M., Wack, C., Charpentier, E., Campana, F. & Vij, R. (2017) A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood, 129, 3294-3303.

Merlini, G., Wechalekar, A.D. & Palladini, G. (2013) Systemic light chain amyloidosis: an update for treating physicians. Blood, 121, 5124-5130.

Milani, P., Merlini, G. & Palladini, G. (2017) Novel Therapies in Light Chain Amyloidosis. Kidney International Reports, 3, 530-541.

Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., Garate, S., Jelinek, T., Segura, V., Moreno, C., Merino, J., Rodriguez-Otero, P., Panizo, C., Prosper, F., San-Miguel, J. F. & Paiva, B. (2019) The Mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 25, 3176-3187.

Muchtar, E., Gertz, M.A., Kumar, S.K., Lacy, M.Q., Dingli, D., Buadi, F.K., Grogan, M., Hayman, S.R., Kapoor, P., Leung, N., Fonder, A., Hobbs, M., Hwa, Y.L., Gonsalves, W., Warsame, R., Kourelis, T.V., Russell, S., Lust, J.A., Lin, Y., Go, R.S., Zeldenrust, S., Kyle, R.A., Rajkumar, S.V. & Dispenzieri, A. (2017) Improved outcomes for newly diagnosed AL amyloidosis over the years 2000-2014: cracking the glass ceiling of early death. Blood, 129, 2111-2119.

Nuvolone, M. & Merlini, G. (2017) Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis. Expert Opinion on Therapeutic Targets, 21, 1095-1110.

O’Nuallain, B., Allen, A., Kennel, S.J., Weiss, D.T., Solomon, A. & Wall, J.S. (2007) Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry, 46, 1240-1247.

Palladini, G. & Merlini, G. (2016) What is new in diagnosis and management of light chain amyloidosis? Blood, 128, 159-168.

Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., Basset, M., Hawkins, P., Merlini, G. & Wechalekar, A.D. (2015) A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood, 126, 612-615.

Palladini, G., Milani, P., Foli, A., Basset, M., Russo, F., Perlini, S. & Merlini, G. (2017) A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. Blood, 129, 2120-2123.

Popat, R., Dowling, E., Achhala, S., Pandit, D., Rabin, N., Kyriakou, C., Mackinnon, S., Yong, K. & Wechalekar, A. (2018) Real world data of the impact of first cycle daratumumab on multiple myeloma and AL amyloidosis services. British Journal of Haematology, 182, 936-939.

Prothena Discontinues Development of NEOD001 for AL Amyloidosis (2019). Prothena Corporation plc. Available at: http://ir.prothena.com/news-releases/news-release-details/prothena-discontinues-development-neod001-al-amyloidosis [Accessed June 9, 2019].

Prothena Reports Results from the Phase 3 VITAL Amyloidosis Study of NEOD001 (birtamimab) in AL Amyloidosis (2019) Prothena Corporation plc. Available at: http://ir.prothena.com/news-releases/news-release-details/prothena-reports-results-phase-3-vital-amyloidosis-study-neod001 [Accessed June 9, 2019].

Renz, M., Torres, R., Dolan, P.J., Tam, S.J., Tapia, J.R., Li, L., Salmans, J.R., Barbour, R.M., Shughrue, P.J., Nijjar, T., Schenk, D., Kinney, G.G. & Zago, W. (2016) 2A4 binds soluble and insoluble light chain aggregates from AL amyloidosis patients and promotes clearance of amyloid deposits by phagocytosis †. Amyloid, 23, 168-177.

Richards, D.B., Cookson, L.M., Berges, A.C., Barton, S.V., Lane, T., Ritter, J.M., Fontana, M., Moon, J.C., Pinzani, M., Gillmore, J.D., Hawkins, P.N. & Pepys, M.B. (2015) Therapeutic clearance of amyloid by antibodies to serum amyloid P component. New England Journal of Medicine, 373, 1106-1114.

Richards, D.B., Cookson, L.M., Barton, S.V., Liefaard, L., Lane, T., Hutt, D.F., Ritter, J.M., Fontana, M., Moon, J.C., Gillmore, J.D., Wechalekar, A., Hawkins, P.N. & Pepys, M.B. (2018) Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis. Science Translational Medicine, 10, eaan3128.

Sanchorawala, V., Seldin, D.C., Magnani, B., Skinner, M. & Wright, D.G. (2005) Serum free light-chain responses after high-dose intravenous melphalan and autologous stem cell transplantation for AL (primary) amyloidosis. Bone Marrow Transplantation, 36, 597-600.

Sanchorawala, V., Sun, F., Quillen, K., Sloan, J.M., Berk, J.L. & Seldin, D.C. (2015) Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience. Blood, 126, 2345-2347.

Sanchorawala, V., Palladini, G., Kukreti, V., Zonder, J.A., Cohen, A.D., Seldin, D.C., Dispenzieri, A., Jaccard, A., Schönland, S.O., Berg, D., Yang, H., Gupta, N., Hui, A.-M., Comenzo, R.L. & Merlini, G. (2017) A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory light-chain (AL) amyloidosis. Blood, 130, 597-605.

Sanchorawala, V., Sarosiek, S., Sloan, J.M., Brauneis, D., Migre, M.E., Mistark, M., Santos, S., Cruz, R., Fennessey, S. & Shelton, A.C. (2018) Safety, tolerability and response rates of daratumumab in patients with relapsed light chain (AL) amyloidosis: results of a Phase II study. Blood, 132, 2005-2005.

Scott, A.M., Allison, J.P. & Wolchok, J.D. (2012) Monoclonal antibodies in cancer therapy. Cancer Immunity, 12, 14.

Search | GSK (2019) Available at: https://www.gsk.com/en-gb/search/ [Accessed October 11, 2019].

Seckinger, A., Hillengass, J., Emde, M., Beck, S., Kimmich, C., Dittrich, T., Hundemer, M., Jauch, A., Hegenbart, U., Raab, M.-S., Ho, A.D., Schönland, S. & Hose, D. (2018) CD38 as immunotherapeutic target in light chain amyloidosis and multiple myeloma - association with molecular entities, risk, survival, and mechanisms of upfront resistance. Frontiers in Immunology, 9, Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062598/ [Accessed January 7, 2019].

Sher, T., Fenton, B., Akhtar, A. & Gertz, M.A. (2016) First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood, 128, 1987-1989.

Sidana, S., Tandon, N., Gertz, M.A., Dispenzieri, A., Buadi, F.K., Lacy, M.Q., Dingli, D., Fonder, A.L., Hayman, S.R., Hobbs, M.A., Gonsalves, W.I., Hwa, Y.L., Kapoor, P., Kyle, R.A., Leung, N., Go, R.S., Lust, J.A., Russell, S.J., Zeldenrust, S.R., Rajkumar, S.V., Hogan, W.J. & Kumar, S.K. (2018) Impact of prior melphalan exposure on stem cell collection in light chain amyloidosis. Bone Marrow Transplantation, 53, 326-333.

Tennent, G.A., Lovat, L.B. & Pepys, M.B. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proceedings of the National Academy of Sciences, USA, 92, 4299-4303.

Topp, M.S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Kroenke, J., Facon, T., Einsele, H. & Munzert, G. (2018) Treatment with AMG 420, an anti-B-cell maturation antigen (BCMA) bispecific T-cell engager (BiTE®) antibody construct, induces minimal residual disease (MRD) negative complete responses in relapsed and/or refractory (R/R) multiple myeloma (MM) patients: results of a first-in-human (FIH) Phase I dose escalation study. Blood, 132, 1010.

Wall, J.S., Kennel, S.J., Stuckey, A.C., Long, M.J., Townsend, D.W., Smith, G.T., Wells, K.J., Fu, Y., Stabin, M.G., Weiss, D.T. & Solomon, A. (2010) Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood, 116, 2241-2244.

Wall, J.S., Kennel, S.J., Williams, A., Richey, T., Stuckey, A., Huang, Y., Macy, S., Donnell, R., Barbour, R., Seubert, P. & Schenk, D. (2012) AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS ONE, 7, e52686.

Wall, J.S., Williams, A.D., Foster, J.S., Richey, T., Stuckey, A., Macy, S., Wooliver, C., Campagna, S.R., Tague, E.D., Farmer, A.T., Lands, R.H., Martin, E.B., Heidel, R.E. & Kennel, S.J. (2018) Bifunctional amyloid-reactive peptide promotes binding of antibody 11-1F4 to diverse amyloid types and enhances therapeutic efficacy. Proceedings of the National Academy of Sciences, USA, 115, E10839-E10848.

Wyngaert, Z.V.D., Carpentier, B., Pascal, L., Lionne, P., Leduc, I., Srour, M., Vasseur, M., Demarquette, H., Herbaux, C., Manier, S., Hieulle, J., Bossard, J.-B., Barbieux, S., Chauvet, P., Willaume, A., Nudel, M., Simonnet, A., Bories, C., Gibier, J.-B., Facon, T., Boyle, E.M. (2018) Efficacy and safety of daratumumab in a frail real-life relapsed or refractory systemic light-chain amyloidosis population (AL): report on 15 cases from the North of France. Blood, 132, 5660.

Zhou, P., Kugelmass, A., Toskic, D., Warner, M., Lee, L.X., Fogaren, T., Varga, C. & Comenzo, R.L. (2018) Seeking AL amyloidosis very early: the SAVE trial - identifying clonal lambda light chain genes in patients with MGUS or smoldering multiple myeloma. Blood, 132, 1903.